AbbVie Inc. saw a significant drop in its stock price after two mid-stage trials for its schizophrenia treatment, emraclidine, failed to meet their primary goal of showing a statistically significant improvement in symptom severity.
This setback presents a challenge for AbbVie, especially considering its recent acquisition of Cerevel Therapeutics for $8.7 billion. The company plans to analyze the trial data to determine its next steps.
The failure of the trials has raised concerns about the future prospects of AbbVie's schizophrenia treatment. However, the company remains committed to finding a solution and will use the trial data to inform its decision-making process.